Health TrialsbyHealthPanel

ECG Abnormalities

3

Review clinical trials related to ECG Abnormalities. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Healthy Individuals H

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in healthy individuals, who live permanently \>2600m.

Participants needed: 14
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Silvia Ulrich SomainiUpdated: Sep 3, 2026Locations: 1
Eligibility criteria

Adults aged 18-80 years and of all genders [+3]

Age <18 years or >80 years [+4]

Read more
Status: Not yet recruiting

Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH

To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in patients with pulmonary arterial hypertension PAH, who live permanently \>2600m.

Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Silvia Ulrich SomainiUpdated: Sep 3, 2026Locations: 1
Eligibility criteria

Adult patients aged 18-80 years and of all genders [+5]

Age <18 years or >80 years [+8]

Read more
Status: Not yet recruiting

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.

Participants needed: 196
Trial details
Biological sex: AllType: InterventionalSponsor: IRCCS Policlinico S. DonatoUpdated: Jan 23, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years [+3]

Clinically significant cardiovascular diseases (atrial fibrillation, congestive... [+2]

Read more